For UK pharmaceutical and life sciences leaders
Waiting for approval to start HCP education costs you the launch
Brands that begin disease awareness and prescriber education only after regulatory sign-off consistently face slower uptake. By the time approval lands, rivals who built the market early are already embedded in clinical thinking.
Two minutes. Solva follows up with specific pre-launch education options.
- Low awareness among HCPs of unmet needs or new therapeutic approaches at the time of product launch
- Slower than anticipated uptake of new medicines post-NICE approval
- Competitors gaining an early foothold due to more proactive pre-launch engagement
- Missed opportunities to establish clinical champions and build advocacy before product availability.
- Increased pressure on sales teams to drive rapid uptake post-launch
- Inefficient allocation of marketing resources due to reactive rather than proactive strategies
- Sub-optimal peak sales and reduced overall product lifecycle revenue
- Increased cost-per-acquisition for new prescriptions due to intensified post-launch marketing efforts
- Delayed patient access to innovative treatments that could improve outcomes
- Slower adoption of new clinical guidelines or best practices
- Perception of the company as slow to innovate or bring value to the UK market
- Erosion of trust with HCPs who feel inadequately informed
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
Pharmaceutical launches that begin HCP education and disease awareness only after regulatory approval consistently underperform versus those that build market understanding during the pre-launch phase. UK market access timelines mean that waiting for NICE guidance before engaging HCPs creates a 12–24 month lag in prescribing uptake.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.